The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids.
Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.
AbbVie’s Imbruvica (ibrutinib) has gained its fourth Breakthrough Therapy Designation from the FDA - this time for the treatment of chronic graft versus host disease (cGVHD) after the failu
After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho